Nancy E. Denyes
2020
In 2020, Nancy E. Denyes earned a total compensation of $625.3K as General Counsel at aTYR PHARMA, a 39% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $116,400 |
|---|---|
| Option Awards | $148,121 |
| Salary | $350,075 |
| Other | $10,661 |
| Total | $625,257 |
Denyes received $350.1K in salary, accounting for 56% of the total pay in 2020.
Denyes also received $116.4K in non-equity incentive plan, $148.1K in option awards and $10.7K in other compensation.
Rankings
In 2020, Nancy E. Denyes' compensation ranked 10,366th out of 13,090 executives tracked by ExecPay. In other words, Denyes earned more than 20.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,366 out of 13,090 | 21st |
Division Manufacturing | 4,437 out of 5,621 | 21st |
Major group Chemicals And Allied Products | 1,834 out of 2,254 | 19th |
Industry group Drugs | 1,606 out of 1,954 | 18th |
Industry Biological Products, Except Diagnostic Substances | 364 out of 411 | 11th |
Source: SEC filing on March 23, 2021.
Denyes' colleagues
We found two more compensation records of executives who worked with Nancy E. Denyes at aTYR PHARMA in 2020.